108 results Webinar: The contraversial Bayer judgment and its potential impact on patent litigation in Europe Philippe Campolini, IP partner at Stibbe in Brussels, acts as panelist in a webinar organised by EPLAW (the European Patent Lawyers Association) on the contraversial Bayer judgment and its potential impact on patent litigation in Europe. Stibbe advises KBC Securities Stibbe assisted KBC Securities as underwriters on the IPO of ThromboGenics on Euronext Brussels. Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products. Stibbe advises on the contemplated IPO of Agendia Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products. Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency. Stibbe advises worldwide seeds leader Stibbe assisted a worldwide seeds leader in negotiations on cooperation deals with competitors. Stibbe advises pharmaceutical multinational Stibbe assisted a pharmaceutical multinational in complex litigations. Stibbe advises on the IPO of Tornier Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix. Mini-symposium “De accountant – Paard van Troje?” Op dinsdag 21 mei organiseert de afdeling Corporate Criminal Law & Investigations van Stibbe een mini-symposium rond het thema van de accountant als pseudo-opsporingsambtenaar en de controlecliënt als potentiële verdachte. Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products. Stibbe advises Canon Medical Systems Stibbe advised Canon Medical Systems on the acquisition of Dutch medical equipment manufacturer Fysicon. Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding. Het federale regeerakkoord door een publiekrechtelijke bril De nieuwe federale regering, die zichzelf een echte “hervormingsregering” noemt, heeft ambitieuze plannen voor het publiekrecht. In deze blogpost ontdek je enkele belangrijke hervormingen die de komende vijf jaar op de agenda staan. HagaZiekenhuis beboet voor datalek Enkele maanden geleden vierden we de eerste verjaardag van de Algemene Verordening Gegevensbescherming (AVG) met een uitgebreide beschouwing over de belangrijkste ontwikkelingen uit het eerste jaar van de verordening. The European Health Data Space (EHDS): new opportunities and obligations for healthcare institutions The European Health Data Space (EHDS) will enter into force on 25 March 2025. The aim of the new European Regulation (EU) 2025/327 on the EHDS is to optimise the exchange of and access to health information within the EU. Francisca Ribeiro Bártolo Senior Associate Amsterdam Pagination Previous page Page 3 Page 4 Page 5 Current page 6
Webinar: The contraversial Bayer judgment and its potential impact on patent litigation in Europe Philippe Campolini, IP partner at Stibbe in Brussels, acts as panelist in a webinar organised by EPLAW (the European Patent Lawyers Association) on the contraversial Bayer judgment and its potential impact on patent litigation in Europe.
Stibbe advises KBC Securities Stibbe assisted KBC Securities as underwriters on the IPO of ThromboGenics on Euronext Brussels.
Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.
Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.
Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.
Stibbe advises worldwide seeds leader Stibbe assisted a worldwide seeds leader in negotiations on cooperation deals with competitors.
Stibbe advises pharmaceutical multinational Stibbe assisted a pharmaceutical multinational in complex litigations.
Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix.
Mini-symposium “De accountant – Paard van Troje?” Op dinsdag 21 mei organiseert de afdeling Corporate Criminal Law & Investigations van Stibbe een mini-symposium rond het thema van de accountant als pseudo-opsporingsambtenaar en de controlecliënt als potentiële verdachte.
Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.
Stibbe advises Canon Medical Systems Stibbe advised Canon Medical Systems on the acquisition of Dutch medical equipment manufacturer Fysicon.
Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.
Het federale regeerakkoord door een publiekrechtelijke bril De nieuwe federale regering, die zichzelf een echte “hervormingsregering” noemt, heeft ambitieuze plannen voor het publiekrecht. In deze blogpost ontdek je enkele belangrijke hervormingen die de komende vijf jaar op de agenda staan.
HagaZiekenhuis beboet voor datalek Enkele maanden geleden vierden we de eerste verjaardag van de Algemene Verordening Gegevensbescherming (AVG) met een uitgebreide beschouwing over de belangrijkste ontwikkelingen uit het eerste jaar van de verordening.
The European Health Data Space (EHDS): new opportunities and obligations for healthcare institutions The European Health Data Space (EHDS) will enter into force on 25 March 2025. The aim of the new European Regulation (EU) 2025/327 on the EHDS is to optimise the exchange of and access to health information within the EU.